Ulysses Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,000
| Closed | -$1.22M | – | 59 |
|
|
2025
Q1 | $1.22M | Hold |
15,000
| – | – | 0.18% | 26 |
|
|
2024
Q4 | $1.35M | Sell |
15,000
-6,500
| -30% | -$585K | 0.22% | 31 |
|
|
2024
Q3 | $2.12M | Buy |
21,500
+4,000
| +23% | +$395K | 0.2% | 27 |
|
|
2024
Q2 | $1.62M | Hold |
17,500
| – | – | 0.23% | 30 |
|
|
2024
Q1 | $1.66M | Buy |
17,500
+13,000
| +289% | +$1.23M | 0.14% | 32 |
|
|
2023
Q4 | $402K | Buy |
+4,500
| New | +$402K | 0.04% | 35 |
|
|
2023
Q3 | – | Sell |
-15,000
| Closed | -$1.25M | – | 52 |
|
|
2023
Q2 | $1.25M | Sell |
15,000
-2,500
| -14% | -$208K | 0.11% | 30 |
|
|
2023
Q1 | $1.33M | Buy |
17,500
+600
| +4% | +$45.7K | 0.28% | 28 |
|
|
2022
Q4 | $1.4M | Buy |
16,900
+11,900
| +238% | +$988K | 0.34% | 22 |
|
|
2022
Q3 | $397K | Buy |
+5,000
| New | +$397K | 0.06% | 37 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 61 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 58 |
|
|
2017
Q3 | – | Sell |
-10,000
| Closed | -$771K | – | 55 |
|
|
2017
Q2 | $771K | Buy |
+10,000
| New | +$771K | 0.1% | 41 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 47 |
|